Ang isang kamakailang pag-aaral ay nagmumungkahi na ang isang dosis ng Pfizer/BioNTech mRNA na bakuna BNT162b2 magbigay ng proteksyon laban sa mga bagong variant sa imga indibidwal na may naunang impeksyon.
Kasalukuyang isinasagawa ang malawakang programa ng pagbabakuna laban sa pandemyang COVID-19. Kasabay nito, may mga ulat ng paglitaw ng bago mga pagkakaiba-iba ng pag-aalala of SARS-CoV-2 virus. With the countries like UK having successfully given first dose to significant section of population, the question is often raised about effectiveness of single dose of COVID vaccine in providing adequate protection against the new variant of SARS-CoV-2 virus.
Ang isang kamakailang pag-aaral ay tumingin sa aspetong ito para sa Pfizer's mRNA vaccine. The researchers investigated if single dose vaccination provides cross protective immunity to variant.
Sa pagsusuri ng mga tugon ng T at B cell pagkatapos ng pagbabakuna sa unang dosis gamit ang Pfizer/BioNTech bakuna ng mRNA BNT162b2 in healthcare workers, the researchers found that those with prior infections had enhanced T cell immunity, antibody secreting memory B cell response to spike and neutralizing antibodies effective against B.1.1.7 and B.1.351. On the other hand, in individuals without prior infection, the single dose of the vaccine showed reduced immune response against variant. B.1.1.7 and B.1.351 spike mutations.
***
Source:
Reynolds C., Pade C., et al 2021. Prior SARS-CoV-2 infection rescues B and T cell responses to variant after first vaccine dose. Science. Published 30 Apr 2021: eabh1282. DOI: https://doi.org/10.1126/science.abh1282
